A New Preventative Strategy Targeting a Specific Novel Protein against Human Bone Metastases

自1981年以来，我国的主要死因一直是癌症。2002年死于癌症的总人数达到304,286人，死亡率为241.5/10万，占2002年总死亡人数的31.0%。骨转移见于25%-50%的晚期癌症患者，据认为目前有7万-15万晚期癌症患者患有骨转移。骨骼是癌症转移的常见部位。维持这些患者的生活质量是一个紧迫的问题，以帮助这些患者过上完全有尊严的生活。因此，我们正在利用医学技术，利用蛋白质组学的方法来筛选骨转移的分子靶蛋白，以期以较低的成本进行早期诊断。根据卫生、劳动和福利部、文部省、体育部、科技部和经济部的《人类基因组/遗传学研究伦理指南》，患者样本捐赠者的姓名被盲化，Tra…更多，和行业，和FDA 21 CFR第11部分。使用血清中的蛋白质组学模式通过SELDI-TOF(BioRad)识别骨转移肿瘤。在47例肝癌患者中进行了一项前瞻性研究，以确定哪些蛋白具有特征并预测骨转移。在这些患者中，有11例发生了骨转移，在所有患者的骨显像证实骨转移之前，该蛋白被鉴定出来。此结果的灵敏度为100%。此外，在这些患者中，有10例出现了蛋白质峰值。目前，由于骨显像结果没有发现骨转移，后续调查正在进行中。我们鉴定的蛋白质的一个重要特征是，在这些患者中，平均在确诊前6-11个月就可以检测到它，远远早于骨核素成像可以检测到的骨转移。此外，我们从曲线下的区域用质谱仪对该蛋白进行了定量，发现该蛋白在血清中持续升高，直到骨显像证实骨转移时，然后在放射治疗开始后下降。[该蛋白显示以下作为骨转移生物标志物的重要意义]1.患者准备测定的是血清。测量时间短。该蛋白比骨显像更早被识别。[该蛋白对骨转移具有以下重要的临床意义]1。能够预防骨转移。我们可以制造这种蛋白质的抑制剂。对预防骨转移药物的展望。骨转移的痛苦将永远消失。我们利用蛋白质组学技术确定了一种新的蛋白质作为骨转移的分子靶点，并展示了它在低成本早期诊断中的潜在用途。现在需要进行大规模的临床试验，以证明这种方法的有效性，但使用这种蛋白进行早期诊断的潜力也可能使未来对骨转移的治疗更加有效。较少

The leading cause of death in our country has been cancer since 1981. The total number of deaths from cancer reached 304,286 in 2002, with a mortality rate of 241.5 per 100,000, accounting for 31.0% of all deaths in 2002. Bone metastasis is found in 25-50% of terminal cancer patients, and it is thought that 70,000-150,000 terminal-stage cancer patients are presently suffering from bone metastasis. Bones are common sites for cancer metastases. Maintaining the QOL of these patients is an urgent concern in order to help these patients live with full dignity. Therefore we are using medical technology to identify molecular target proteins of bone metastasis using proteomics in order to facilitate early diagnosis at low cost. Names of the donors of patient samples were blinded in accordance with the 'Ethical Guidelines for Human Genomic/Genetic Studies' of the Ministry of Health, Labor, and Welfare, Ministry of Education, Culture, Sports, Science, and Technology, and Ministry of Economy, Tra … More de, and Industry, and the FDA 21 CFR part 11. Use of proteomics patterns in serum to identify bone metastasis tumor by SELDI-TOF (BioRad). A prospective study was undertaken in 47 patients with liver cancer, to identify which proteins were characteristic and predictive of bone metastasis. Of these patients, bone metastasis developed in 11 cases, and this protein was identified before bone metastasis was confirmed in bone scintigraphy of all patients. This result yielded a sensitivity of 100%. Also, among these patients, peak values of the protein were found in 10 cases. At present, the follow-up investigation is under way because the results of bone scintigraphy did not reveal bone metastasis. An important characteristic of the protein we identified was that it was detectable at about average at 6-11 months before diagnosis in these patients, much earlier than bone metastases can be imaged by bone scintigraphy. In addition, we quantified this protein from the areas under the curves by mass spectrometry, and found that the protein continued to increase in serum up to the time when bone metastasis was confirmed by bone scintigraphy and then decreased after the start of radiotherapy treatment.[This protein shows below important significance to become biomarker of bone metastasis]1. Preparation of the patient to measure is serum.2. Measurement time is short.3. This protein recognized earlier than bone scintigraphy.[This protein shows below important clinical significance to bone metastasis]1. Prevention of bone metastasis is enabled.2. We can make inhibitor of this protein. Expectation to pharmaceuticals for prevention of bone metastasis.3. The pain of bone metastasis will be gone eternally.4. Macrobiotic expectation of the cancer patients.We have used proteomics technology to identify a novel protein as a molecular target for bone metastasis and demonstrated its potential use for early diagnosis at low cost. Large-scale clinical trials will now be needed, to prove the usefulness of this approach, but the potential offered for early diagnosis using this protein could also enable far more effective treatment for bone metastasis in the future. Less